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Abstract
Background: To determine the efficacy and safety of heparin (unfractionated heparin (UFH) or
low-molecular-weight-heparin (LMWH)) and fondaparinux in improving the survival of patients
with cancer.
Methods: We conducted in January 2007 a comprehensive search for relevant randomized clinical
trials (RCTs). We used a standardized form to extract in duplicate data on methodological quality,
participants, interventions and outcomes of interest including all cause mortality, thromboembolic
events, and bleeding events. We assessed the methodological quality for each outcome by grading
the quality of evidence using the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) methodology
Results: Of 3986 identified citations, we included 5 RCTs, none of which evaluated fondaparinux.
The quality of evidence was moderate for survival, low for major and minor bleeding, and very low
for DVT. Heparin therapy was associated with a statistically and clinically significant survival benefit
(hazard ratio (HR) = 0.77; 95%CI = 0.65–0.91). In subgroup analyses, patients with limited small cell
lung cancer experienced a clear survival benefit (HR = 0.56; 95%CI = 0.38–0.83). The survival
benefit was not statistically significant for either patients with extensive small cell lung cancer (HR
= 0.80; 95%CI = 0.60–1.06) or patients with advanced cancer (HR = 0.84; 95%CI = 0.68–1.03). The
increased risk of bleeding with heparin was not statistically significant (relative risk (RR) = 1.78;
95%CI = 0.73–4.38).
Conclusion: This review suggests a survival benefit of heparin in cancer patients in general, and in
patients with limited small cell lung cancer in particular.
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Background
Researchers have hypothesized that heparin improves
outcomes in cancer patients through an antitumor effect
in addition to its antithrombotic effect [1]. In a 1992 trial
comparing nadroparin, a low-molecular-weight-heparin
(LMWH), to unfractionated heparin (UFH) in patients
with deep vein thrombosis (DVT), nadroparin unexpect-
edly reduced mortality in the subgroup of cancer patients
[2]. At the same time, the risk of bleeding with anticoagu-
lants is higher in patients with cancer compared to those
without cancer [3]. Heparins are also known to cause
thrombocytopenia [4].
A 1999 systematic review of the effects of UFH on survival
in patients with malignancy found three trials of high
methodological quality but with conflicting results. [5]
Since then reports on several randomized controlled trials
(RCTs) on this subject have been published [6,7], includ-
ing at least one study in patients with small cell lung can-
cer [8]. The purpose of this study was to determine the
efficacy and safety of parenteral anticoagulation in
improving survival of patients with cancer in general and
lung cancer in particular.
Methods
Data Sources and Searches
The search was part of a comprehensive search for studies
of anticoagulation in patients with cancer. We electroni-
cally searched in January 2007 the following databases
from the date of their inception: The Cochrane Central
Register of Controlled Trials, MEDLINE, EMBASE and ISI
the Web of Science (see Additional file 1). We also hand
searched the conference proceedings of the American
Society of Clinical Oncology and of the American Society
of Hematology. We reviewed the reference lists of
included papers and used the related article feature in
PubMed. We applied no language restrictions.
Study Selection
Two reviewers independently screened the titles and
abstracts for eligibility. We retrieved the full texts of arti-
cles judged as potentially eligible by at least one reviewer.
Two reviewers then independently screened the full texts
articles for eligibility and resolved their disagreements by
discussion. We included abstracts only if authors supplied
us with the necessary information about their methods
and results.
We included only RCTs. Study participants had to have
cancer but no indication for prophylactic or therapeutic
anticoagulation. Interventions included one of the three
classes of parenteral anticoagulants approved for clinical
use: UFH, LMWH, and/or fondaparinux. The review out-
comes were: survival (primary outcome), symptomatic
DVT, symptomatic pulmonary embolism, major bleed-
ing, minor bleeding, and thrombocytopenia. DVT and PE
events had to be diagnosed using objective diagnostic
tests.
Data Extraction and Quality Assessment
Two reviewers independently extracted data using a stand-
ardized form and resolved their disagreements by discus-
sion. We contacted authors for incompletely reported
data.
We extracted time to event data by abstracting the log(haz-
ard ratio) and its variance from trial reports; if these were
not reported, we digitised the published Kaplan-Meier
survival curves and estimated the log(hazard ratio) and its
variance using Parmar's methods [9]. We performed these
calculations in Stata 9, using a specially written program,
which yielded the reported log(HR) and variance when
used on the data presented in Table V of Parmar 1998 [9].
We also extracted categorical data necessary to conduct
intention-to-treat (ITT) analyses. We collected all cause
mortality at one year (time point defined a priori) and at
2 years (time point defined post hoc based upon results
reported in the individual RCTs).
We assessed the following methodological criteria: alloca-
tion concealment, blinding (patient, provider, outcome
assessor, data analyst), whether the analysis followed the
ITT principle, whether study was stopped early for benefit,
and percentage of follow-up. We assessed the methodo-
logical quality for each outcome by grading the quality of
evidence using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) methodol-
ogy [10].
Analysis
We calculated the agreement between the two reviewers
for eligibility assessment using kappa statistic. We created
an inverted funnel plot for the primary outcome to check
for possible publication bias.
For time to event data, we pooled the log(HR)s using a
random-effects model and the generic inverse variance
facility of RevMan 4.2. For categorical data, we calculated
the relative risk (RR) separately for each study for the inci-
dence of outcomes by treatment arm. We then pooled the
results of the different studies using a random-effects
model.
We measured homogeneity across studies using the I2 sta-
tistics [11] and considered the following classification of
heterogeneity based on the value of I2 (Higgins, personal
communication): 0–50 = low; 30–80 = moderate and
worthy of investigation; 60–100 = severe and worthy of
understanding; 95–100 = aggregate with major caution.Journal of Experimental & Clinical Cancer Research 2008, 27:4 http://www.jeccr.com/content/27/1/4
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We planned to explore heterogeneity by conducting sub-
group analyses based on the type of intervention and the
characteristics of participants. We also planned for sensi-
tivity analysis excluding poor quality trials.
Results
Figure 1 shows the trial flow. The search strategy identified
3986 citations, including 322 duplicates. The title and
abstract screening of the 3664 unique citations identified
51 as potentially eligible. The full text screening of the 51
citations identified 5 eligible RCTs published as full
reports [6,7,12-14]. We identified 4 earlier published
abstracts for 3 of the 5 included RCTs [12,15-17]. We also
identified six eligible studies published as abstracts but we
were unable to obtain the needed data from the authors
[18-23]. Agreement between reviewers for eligibility was
excellent (kappa = 0.94).
Included studies
The five included studies recruited 1189 participants and
reported follow-up data on 1175 [6-8,13,14]. The inter-
vention was UFH in one study [13] and LMWH in four [6-
8,14] and fondaparinux in none. Table 1 details the char-
acteristics of these studies.
Methodological quality of included studies
Allocation was adequately concealed in four studies
[6,7,13,14] and it was unclear whether it was adequately
concealed in the fifth study [8]. Two studies blinded par-
ticipants, caregivers, and outcome assessors [7,14], one
study blinded patients and caregivers [6], one study
blinded outcome assessors and data analysts [13], and
one study blinded only outcome assessors [8]. The lowest
percentage of follow up in the five studies was 97%. Only
one study did not use ITT analysis [14]. One study was
stopped early for insufficient accrual [14]. According to
GRADE methodology, the quality of evidence was moder-
ate for survival, low for major and minor bleeding, and
very low for DVT (Table 2).
Quantitative results
There was low to moderate heterogeneity (I2 = 47.5%) for
the survival outcome. The small number of trials permit-
ted subgroup analyses only for the subgroups of patients
with small cell lung cancer (SCLC) and with "advanced
cancer" (as defined in individual studies). The inverted
funnel plot for the primary outcome of mortality at 1 year
did not suggest publication bias (Figure 2).
All cause mortality
Based on a pooled estimate from the 5 RCTs, heparin was
associated with a statistically significant survival benefit
(HR = 0.77; 95%CI = 0.65 – 0.91; I2 = 47%) (Figure 3).
Excluding the study by Lebeau et al. [13] (the only study
using UFH) then the study by Altinbas et al. [8] (in which
the allocation was not clearly concealed) yielded esti-
mates similar to the primary meta-analysis.
The categorical analysis confirmed those results with a sta-
tistically significant reduction of mortality at 12 months
(RR = 0.87; 95%CI = 0.80–0.95) and at 24 months (RR =
0.92; 95%CI = 0.86 – 0.99).
Small cell lung cancer
In patients with limited SCLC, heparin was associated
with a statistically significant survival benefit (HR = 0.56;
Inverted funnel plot for randomized controlled trials of  parenteral anticoagulation in cancer patients Figure 2
Inverted funnel plot for randomized controlled trials of 
parenteral anticoagulation in cancer patients.
The trial flow Figure 1
The trial flow.
3986 citations identified and screened for 
retrieval
51 potentially eligible studies retrieved for 
more detailed evaluation  
36 studies excluded: 
o  intervention was topical heparin (1) or 
intraportal infusion of heparin (2) 
o  study included no cancer patients (2) 
o  no survival outcome (2) 
o  study design was not a RCT (16) 
o  letter to the editor or editorial (8) 
o  publication was a review (5). 
15 potentially eligible RCTs  
5 RCTs included in the systematic review 
10 RCTs excluded: 
o  abstract later published in full text 
included in this review (4) 
o  abstracts for which we were not able to 
obtain data from the authors (6)
322 duplicates 
5 RCTs included in the meta-analysis Journal of Experimental & Clinical Cancer Research 2008, 27:4 http://www.jeccr.com/content/27/1/4
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95%CI = 0.38 – 0.83), with no heterogeneity between tri-
als (I2 = 0) (Figure 4). In the categorical analysis, heparin
was associated with a statistically significant reduction of
mortality at 12 months (RR = 0.60; 95%CI = 0.42–0.87)
but not at 24 months (RR = 0.90; 95%CI = 0.71–1.14).
Excluding the study by Altinbas et al. did not change the
results in terms of statistical significance.
For extensive SCLC, heparin was associated with a non-
statistically significant survival benefit (HR = 0.80; 95%CI
Table 1: Comparative table of randomized controlled trials assessing the effect of heparin on the survival of patients with cancer
Study Methods* Intervention† Participants‡ Outcome 
assessment§
Notes
Lebeau 1994 AC: adequate 
Blinded: outcome 
assessors, data 
analyst ITT analysis: 
yes Study stopped 
early: no
UFH (prophylactic 
dose) vs. no 
intervention for 5 
weeks; in 
combination with 
chemotherapy
Small cell lung cancer both 
limited and extensive; 78% had 
Karnofsky > 80; 277 
randomized and 277 followed 
up (100%); 85% older than 50
Outcomes: 
mortality (at 12, 24, 
and 36 months)
Funding: None; 
maximum follow 
up: 84 months
Kakkar 2004 
(FAMOUS trial)
AC: adequate 
Blinded: patients, 
care givers ITT 
analysis: yes Study 
stopped early: no
LMWH (Dalteparin; 
prophylactic dose) 
vs. placebo for 12 
months; no 
restriction on 
concomitant 
chemotherapy or 
radiotherapy
Different types of with 
advanced stage III or IV 
malignant disease of the breast, 
lung, gastrointestinal tract, 
pancreas, liver, genitourinary 
tract, ovary, or uterus; 
minimum life expectancy 3 
months; 385 randomized, 374 
followed up (97%); no 
withdrawal from treatment; 
median age 61 IQR [53–68]
Outcomes: 
mortality (at 12, 24, 
and 36 months), PE, 
DVT, major 
bleeding, and minor 
bleeding Screening 
testing for DVT/PE: 
None Diagnostic 
testing for DVT/PE: 
not reported
Funding: Pharmacia 
Corp, NY; 
maximum follow 
up: 77 months
Klerk 2005 (MALT 
trial)
AC: adequate 
Blinded: patients, 
care givers, outcome 
assessors ITT 
analysis: yes Study 
stopped early: no
LMWH 
(Nadroparin) vs. 
placebo for 6 weeks; 
2 weeks therapeutic 
dose then 4 weeks 
prophylactic dose; 
no concomitant 
chemotherapy or 
radiotherapy
Different types of solid 
malignant tumours "that could 
not be treated curatively" 
including: colorectal, breast, 
lung, gastric, oesophageal, 
liver, gallbladder, Katskin, 
prostate, pancreatic, cervical, 
urothelial, renal, ovarian, 
melanoma, endomaterial and 
other cancers; minimum life 
expectancy 1 month, stratified 
according to life expectancy (< 
or > 6 months); 302 patients 
randomized, 302 followed up 
(100%); median age 64
Outcomes: 
mortality (at 6, 12, 
and 24 months), 
major bleeding, and 
minor bleeding
Funding: Sanofi 
provided study 
medication; 
maximum follow 
up: 84 months
Altinbas 2004 AC: not reported 
Blinded:outcome 
assessors ITT 
analysis: yes Study 
stopped early: no
LMWH (Dalteparin; 
prophylactic dose) 
vs. placebo for 18 
weeks or less if 
disease progressed; 
in combination with 
chemotherapy
Small cell lung cancer both 
limited and extensive, ECOG 
state < 3; 84 patients 
randomized, 84 patients 
followed up (100%); median 
age 58
Outcomes: 
mortality (at 12 and 
24 months), DVT, 
and minor bleeding 
Screening and 
diagnostic testing 
for DVT: not 
reported
Funding: not 
reported; maximum 
follow up: 33 
months
Sideras 2006 AC: adequate 
Blinded: patients, 
care givers, outcome 
assessors (1st 37% of 
randomized 
patients) ITT 
analysis: no Study 
stopped early for 
insufficient accrual
LMWH (Dalteparin; 
prophylactic dose) 
for unclear duration 
vs. placebo or no 
intervention
Different types of advanced 
cancer with minimum life 
expectancy 12 weeks; ECOG 
state 0–2; 141 randomized, 
138 followed up (98%); no 
withdrawal from treatment; 
median age 67
Outcomes: 
mortality (at 12, 24, 
and 36 months), 
VTE, and major 
bleeding. Screening 
testing for DVT/PE: 
None Diagnostic 
testing for DVT: 
decided by the 
primary clinician
Funding: 
governmentally 
funded, 
pharmaceutical 
company supplied 
drug and placebo; 
maximum follow 
up: 24 months
* AC = allocation concealment; ITT = intention to treat analysis
† LMWH = Low molecular weight heparin; UFH = Unfractionated heparin
‡ ECOG = Eastern Cooperative Oncology Group
§DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolismJournal of Experimental & Clinical Cancer Research 2008, 27:4 http://www.jeccr.com/content/27/1/4
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Table 2: Summary of findings (SoF) table using GRADE methodology
Parenteral anticoagulation for prolonging survival of patients with cancer
Patient or population: Patients with cancer
Settings: Outpatient
Intervention: Parenteral anticoagulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect (95% 
CI)
No of 
Participants 
(studies)
Quality of the 
evidence 
(GRADE)
Comments
Assumed risk Corresponding risk
Control Parenteral 
anticoagulation
Survival Low risk population HR 0.77 (0.65 to 0.91) 1174 (5) ⊕⊕⊕O moderate4
500 per 1000 414 per 1000 (363 to 
468)
Moderate risk population
1000 per 1000 1000 per 1000 (1000 to 
1000)
DVT Low risk population RR 0.61 (0.08 to 4.91) 458 (2) ⊕OOO very low1,2
10 per 1000 6 per 1000 (1 to 49)
High risk population
40 per 1000 24 per 1000 (3 to 196)
Major bleeding Low risk population RR 1.50 (0.26 to 8.8) 814 (3) ⊕⊕OO low1,3
0 per 1000 0 per 1000 (0 to 0)
High risk population
100 per 1000 150 per 1000 (26 to 880)
Minor bleeding Low risk population RR 2.07 (0.78 to 5.51) 760 (3) ⊕⊕OO low1,3
0 per 1000 0 per 1000 (0 to 0)
High risk population
30 per 1000 62 per 1000 (23 to 165)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate.
Very low quality: We are very uncertain about the estimate.
1 The 95% CI includes both negligible effect and appreciable benefit or appreciable harm
2 Out of 5 included studies, only 2 reported DVT
3 Out of 5 included studies, only 3 reported major bleeding
4Result statistically significant in only one subgroup.Journal of Experimental & Clinical Cancer Research 2008, 27:4 http://www.jeccr.com/content/27/1/4
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= 0.60–1.06; I2 = 0) (Figure 4). The results were similarly
non-statistically significant in the categorical analysis at
12 months (RR = 0.93; 95%CI = 0.76 = 1.15) and 24
months (RR = 0.88; 95%CI = 0.65–1.18).
Advanced cancer
Based on a pooled estimate from studies including
patients with advanced cancer [6,7], heparin was associ-
ated with a non-statistically significant survival benefit
(HR = 0.84; 95%CI = 0.68–1.03) (Figure 3), with moder-
ate heterogeneity between trials (I2 = 47%). The effect of
heparin on mortality was borderline significant at 12
months (RR = 0.89; 95%CI = 0.80–1.00) and 24 months
(RR = 0.92; 95%CI = 0.85–1.00).
Klerk et al [7] defined a priori two subgroups of patients
with life expectancy less and greater than 6 months respec-
tively. The HR for survival was 0.64 (95%CI = 0.45–0.90)
for patients with longer life expectancy and 0.88 (95%CI
= 0.62–1.25) for patients with shorter life expectancy)
Venous thromboembolism
Based on pooled estimates from two RCTs [6,8], heparin
therapy was associated with a non-statistically significant
reduction in DVT (RR = 0.61; 95%CI = 0.08–4.91).
Major and minor bleeding
Pooled estimates showed that heparin therapy was associ-
ated with increased bleeding that was non-statistically sig-
nificant for minor bleeding (RR = 2.07; 95%CI = 0.78–
5.51), or major bleeding (RR = 1.50; 95%CI = 0.26–8.80)
or any bleeding (RR = 1.78; 95%CI = 0.73–4.38) (Figure
5). After excluding the study by Altinbas et al. the results
remained non-statistically significant.
Three studies assessed thrombocytopenia as an outcome
but reported no events [7,8,13]. None of the studies
reported participants withdrawing from treatment.
Discussion
Heparin therapy (with either UFH or LMWH) was associ-
ated with a statistically and patient important survival
benefit in cancer patients who had no indication for
parenteral anticoagulation. In subgroup analyses, patients
with limited SCLC experienced a clear survival benefit.
The survival benefit was not statistically significant for
either patients with extensive SCLC or patients with
advanced cancer. The increased risk of bleeding with
heparin was not statistically significant. We did not iden-
tify any study using fondaparinux as the anticoagulant.
The strengths of this study include our systematic
approach to searching, study selection and data extraction
which has minimized the likelihood of missing relevant
studies. The quality of evidence was high for survival; all
included studies were RCTs with moderate percentages of
follow-up and allocation was clearly adequate in all but
one included study. This moderate quality of evidence for
surival, and the low likelihood of publication bias
increase the confidence in the internal validity of our find-
ings. Furthermore, we conducted pooled survival analysis
for the important outcomes.
The effect of heparin therapy on survival in patients with cancer Figure 3
The effect of heparin therapy on survival in patients with cancer.Journal of Experimental & Clinical Cancer Research 2008, 27:4 http://www.jeccr.com/content/27/1/4
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There was a statistically significant reduction in mortality
at 12 months but not at 24 months in patients with lim-
ited SCLC. This difference probably reflects a true differ-
ence of effect at different follow-up periods. Such a
difference might be due to the relatively short overall sur-
vival of patients with SCLC enabling short term but not
long term benefit. It might also be due to the initial con-
tribution of the antithrombotic effect of LMWH. While
this assumption does not contradict a concomitant antitu-
mor effect of LMWH (see below), it acknowledges the
antithrombotic role and its clinical importance in manag-
ing patients with limited SCLC.
The non-significant findings in this study may be due to
the small number of RCTs, of participants and of events.
For example, compared with the data at 12 months, the
results at 6 months tended to be non-significant; the latter
could be explained by a smaller number of events in the
early follow up period. The interpretation of findings is
also limited by not including data from the 7 trials pub-
lished as abstracts only.
Interpretation of the findings of this review is somewhat
limited by the moderate heterogeneity between the results
of different trials, which was not completely explained by
subgroup analyses based on type of cancer. The heteroge-
neity could be related to variety in the stages of cancers,
and in the types, dosing, schedules and duration of
heparin therapy. The relatively small number of studies
and the inclusion of different types of cancer in the same
study precluded us from conducting the necessary sub-
group analyses to explore all of these factors.
The statistically significant survival benefit of heparin in
the subgroup of patients with limited SCLC in this review
and in the subgroup of patients with life expectancy
greater than 6 months in the study by Klerk et al [7] sug-
gest that less ill patients receive greater benefit from
heparin. The CLOT trial [24] supports these findings indi-
rectly; in that study, patients with solid tumors and an
acute venous thromboembolic event had improved sur-
vival if they did not have a metastatic disease at the time
of study entry.
Studies with shorter periods of heparin therapy (i.e. 5 and
6 weeks) [7,13], appear to provide similar benefit as those
with longer periods (i.e. 12 weeks) [6]. The clinical impli-
cation would be major if in fact, prolonging the duration
of therapy does not provide additional benefit while
increasing the risk of side effects (mainly bleeding events).
However, none of the included studies was designed to
address this question.
Lazo-Lannger et al. conducted a systematic review
addressing the same question as this review [25].
Although that review had different inclusion criteria from
our review (in particular, it excluded the trial of Lebeau)
and obtained slightly different estimates of HRs using Par-
mar's methods, it reported similar results: a hazard rate
comparing mortality in the heparin and control arms of
0.83 (95% CI: 0.70 to 0.99). This consistency of results
from independent reviews confirms the robustness of the
findings. However, Lazo-Lannger et al. did not report any
subgroup analysis in patients with small cell lung cancer.
While there are important pitfalls in subgroup analysis,
The effect of heparin therapy on survival in patients with small cell lung cancer Figure 4
The effect of heparin therapy on survival in patients with small cell lung cancer.Journal of Experimental & Clinical Cancer Research 2008, 27:4 http://www.jeccr.com/content/27/1/4
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they serve to generate hypotheses that should further be
explored [26].
"The survival benefit in patients with cancer of anticoagu-
lation is probably only in part mediated through an anti-
thrombotic effect, i.e. through the prevention of fatal
thromboembolic events. In fact, the survival curves of the
included studies show consistent survival benefit beyond
the duration of heparin therapy. Similarly, the meta-anal-
ysis shows a statistically significant survival benefit at 12
months while the duration of heparin therapy in 4 of the
included studies was 5 weeks, 6 weeks, 18 weeks, and 12
months respectively. Experts in the field have attributed
this phenomenon to an antitumor effect of anticoagula-
tion [27,28].
Basic research supports the hypothesis of an antitumor
effect of anticoagulation. Studies have implicated the
tumour-mediated activation of the haemostatic system in
both the formation of tumour stroma and in tumour
metastasis [29-31]. There is also evidence that heparin
inhibits expression of oncogenes, the formation by cancer
cells of thrombin and fibrin induced, and the intravascu-
lar arrest of cancer cells, and thus metastasis [32].
The antitumor effect does not appear to be the same
across anticoagulant classes. In a systematic review of oral
anticoagulation for prolonging survival in patients with
cancer, warfarin improved early survival in patients with
extensive SCLC but not in patients with limited SCLC
[33]. In another systematic review of the initial treatment
of VTE in patients with cancer, LMWH provided a survival
benefit compared with UFH [34]. Finally, for long term
treatment of VTE in this population, LMWH compared
with oral anticoagulation reduced the incidence of venous
thromboembolism although did not provide a survival
benefit [35].
Conclusion
In conclusion, this systematic review suggests a survival
benefit of heparin in cancer patients in general, and in
patients with limited small cell lung cancer in particular.
It also suggests a higher benefit in patients with limited
cancer or a longer life expectancy. The decision for a
patient with cancer to start heparin therapy for survival
benefit should balance the benefits and downsides and
integrate the patient's values and preferences [36].
Patients with a high preference for a short survival prolon-
gation and limited aversion to bleeding who do not con-
sider heparin therapy a burden may opt to use heparin,
while those with aversion to bleeding may not.
Future research should investigate the effects anticoagula-
tion in patients with different types and stages of cancers
comparing different types, dosing and duration of therapy
[37].
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